Iris Energy Limited vs Liquidia Corporation Common Stock — how do they compare? Iris Energy Limited trades at $29.63 (market cap $12.04B), while Liquidia Corporation Common Stock trades at $34.2 (market cap $3.04B). The key difference: Iris Energy Limited is far larger — about 4× Liquidia Corporation Common Stock's market cap, and Liquidia Corporation Common Stock is trading nearer its 52-week high, Iris Energy Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iris Energy Limited for 28 Days and Liquidia Corporation Common Stock for 0 Days on average.
| IREN | LQDA | |
|---|---|---|
Market Cap | $12.04B | $3.04B |
Volume | 77,249,064 | 21,111,778 |
Sector | Technology | Health |
52-Week High | $76.41 | $91.03 |
52-Week Low | $29.31 | $22.02 |
Typical Hold Time | 28 Days | 0 Days |
Enterprise Value | $13.98B | $2.94B |
Signals from Pluang's Aura AI — not financial advice
IREN trades at $34.80, showing no change in the last 24 hours. The stock faces bearish technical signals despite bullish oscillators, with key support at $34. Recent earnings misses and a negative net income margin of -99.38% highlight financial strain, though revenue grew to $501M in 2025. Analyst sentiment remains strongly positive with a consensus price target of $81.00, driven by the company's pivot to AI infrastructure and major contracts with Microsoft and NVIDIA.
The outlook is bifurcated: substantial upside exists if IREN executes its AI transition, but high valuation ratios and persistent losses pose risks. Investors should weigh the aggressive growth projections against current profitability challenges and capital intensity.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →